Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Investor Presentation (2012)
26 slides from Dr. Reddy's Laboratories's investor presentation, Jul 7, 2012
Slide 1: The Dr. Reddy's story
& Y Dr. REDDY'S The Dr. Reddy’s story LIFE CRESEARCH.H O1P.&
Slide 2: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com 2
Slide 3: Our Purpose
Our Purpose Purpose Providing affordable and innovative medicines for healthier lives www.drreddys.com 3
Slide 4: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com 4
Slide 5: Key Milestones: Taking the First Steps (1984-1990)
Key Milestones Taking the First Steps (1984-1990) Established by Dr K Anji Reddy with an initial capital outlay of Rs.25 lakhs 1984 Goes public with listing in Bombay Stock Exchange 1986 Enters international markets with exports of Methyldopa Obtains its first USFDA approval for Ibuprofen API 198
Slide 6: Key Milestones: Expanding and Innovating (1991-1999)
Key Milestones Expanding and Innovating (1991-1999) Formulation exports to Russia commences 1991 1993 Establishes Dr. Reddy's Research Foundation. Drug Discovery program starts Dr. Reddy's Research Foundation files first patent in the US 1995 Becomes first Indian company to out-license an original
Slide 7: Key Milestones: Growing Globally (2000-present)
Key Milestones Growing Globally (2000- present) Cheminor Drugs (A group company) merges with Dr. Reddy‘s 2000 Establishes Reddy US therapeutics in USA Becomes the first pharma company in Asia Pacific, outside of Japan, to list on NYSE 2001 Obtains 1st ever 180-day mkt. exclusivity for a generic
Slide 8: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com 8
Slide 9: Dr. Reddy's Today
Dr. Reddy’s Today Vertically integrated global pharmaceutical company from India Revenues of U.S. $ 2 bn in FY2012 with a CAGR of ~ 20% over the last decade Strong portfolio of businesses, geographies and products Three business segments Pharmaceutical Services & Active Ingredients, Global G
Slide 10: Dr. Reddy's Today: Infrastructure
Dr. Reddy’s Today Infrastructure: 18 manufacturing facilities 8 API manufacturing units (6 FDA-approved plants in India, 1 FDA- approved plant in Mirfield, UK, 1 plant in Mexico) 9 Finished Dosage units (7 Formulation plants in India (2 USFDA approved), 2 USFDA approved plants in USA) 1 Biolog
Slide 11: Our Businesses
Our Businesses Proprietary Products Pharmaceutical Global Generics • Focus on building Services & Active sustainable and profitable • Finished dosage businesses Ingredients in distribution-driven as well branded businesses as doctor-driven markets • Customers include generic • Efforts in Biosimilars
Slide 12: The Last Decade
The Last Decade Built the foundations for a strong business. Moved up the value chain. Strengthened capabilities. Achieved scale and global presence. Acquired to aid growth. Revenues [USD Mn] 1510 1901 1677 1563 1365 1250 Germany & Mexico acquisitions Authorized generic launches 546 463 447 380
Slide 13: Recap - FY12 Revenue
Recap - FY12 Revenue ($ Mn) 2,021 1,639 1,509 1,481 1,241 FY08 FY09 FY10 FY11 FY12 Note: Adjusted for one time impacts . www.drreddys.com 13
Slide 14: Recap - FY12 Global Generics
Recap - FY12 Global Generics ` 7,037 Crs (32% YoY growth) Europe `835 Crs (-1% gr) Russia & Other CIS `1,334 Crs (23% gr) US `3,175 Crs (67% gr) India `1,294 Crs (11% gr) Rest of World `399 Crs (19% gr) www.drreddys.com 14
Slide 15: Recap - FY12: Global Generics
Recap- FY12: Global Generics US $ Million Russia Rouble Million 62% 15% 671 413 5930 6816 FY11 FY12 FY11 FY12 India ` Crs Europe € Mn -10% 11% 1,169 1,294 FY11 FY12 www.drreddys.com 15
Slide 16: Recap - FY12: PSAI
Recap- FY12: PSAI Revenues ` Crs 21% 2,381 1,965 FY11 FY12 www.drreddys.com 16
Slide 17: Recap FY12: API
Recap FY12: API ` 1,852 Crs (21% YoY growth) Europe `564 Crs (29% gr) North America `242 Crs (26% gr) India `359 Crs (37% gr) Rest of World `687 Crs (7% gr) www.drreddys.com
Slide 18: Recap FY12: CPS
Recap FY12:CPS ` 530 Crs (23% YoY growth) Europe `278 Crs (5% gr) North America `185 Crs (48% gr) Rest of World `67 Crs (67% gr) www.drreddys.com
Slide 19: Dr. Reddy's edge in the pharma space
Dr. Reddy’s edge in the pharma space Industry leading chemistry skills which has resulted in several niche product opportunities (eg: fondaparinux, fexofenadine-pseudoephedrine, omeprazole mg, lansoprazole) High vertical integration (~75% of APIs sourced internally) Amongst the leading pipeline in f
Slide 20: Outline
Outline Our Purpose The journey so far: Key Milestones What is Dr. Reddy’s today Key Questions www.drreddys.com 20
Slide 21: Key Questions
Key Questions 1. What are our aspirations for each business ? 2. Why do we believe we will succeed ? www.drreddys.com 21
Slide 22: 1. What are our aspirations?
1. What are our aspirations? Improve depth in key Leadership markets through portfolio Global Generics position expansion and supply in key markets chain excellence Pharmaceutical Create compelling value Services for customers by Partner of & Active leveraging IP, technology Choice Ingredients and c
Slide 23: 2. Why do we believe we will succeed?
2. Why do we believe we will succeed? Key markets Product Focus Supply chain delivery & excellence engine Depth Vertical integration with cost, technology & IP leverage www.drreddys.com 23
Slide 24: Commitment to Sustainability
Commitment to Sustainability Collective Actions – Our DNA of Sustainability OUR SUSTAINABILITY FRAMEWORK Providing Affordable and Innovative Medicines Environment management and Climate Change Being an Employer of Choice Product Responsibility Sustainable Sourcing Caring for Communities
Slide 25: Key Recognitions in FY12
Key Recognitions in FY12 Dr. Reddy's was Dr. Reddy’s was named amongst awarded the Dr. Reddy’s bagged India's Best Thomson Reuters the ICAI Gold Shield Employers in 2011 Innovation Award for Excellence in in a survey 2011 Financial Reporting conducted by for 2010 – 11 Outlook Business Dr. Anji Reddy
Slide 26: Thank You
THANK THANK YOU www.drreddys.com
Dr. Reddy's Laboratories — Investor Presentation (2012) on 6ix